FRESENIUS MEDICAL CARE

MAPPING A DIGITAL FUTURE FOR KIDNEY CARE

Expert call | March 29, 2021

Franklin W. Maddux, MD FACP – CMO



FRESENIUS MEDICAL CARE

Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading "Forward-Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.



DIGITALIZATION ACROSS THE FULL STRATEGIC VISION

FRESENIUS MEDICAL CARE

STRATEGIC VISION

In 2020 Fresenius Medical Care's Management Board outlined our company's strategic vision built around three core areas:

The renal care continuum

Critical care and

Complementary assets.

The organization of the Global Medical Office allows us to comprehensively consider scientific evidence and innovations in order to advance clinical practice on a worldwide basis.



HOW TO ENABLE OUR VISION ON DATA ASSETS?

AS A FULL VERTICAL INTEGRATED COMPANY…

Data analytics teams

Medical experts



Health care professionals

Research & development

Production

~350,000
Dialysis Patients worldwide

>4,000
Own Dialysis clinics in around 50 countries

>50 Mn.
Dialysis Treatments in 2020

HOW TO ENABLE OUR VISION ON DATA ASSETS?

…FRESENIUS MEDICAL CARE IS IN A UNIQUE POSTION OF LEVERAGEING ITS VARIOUS DATA POOLS TO PROVIDE INDIVIDUALIZED AND BEST IN CLASS THERAPIES.

FRESENIUS MEDICAL CARE

Production and service data	**Machine and device data**	**Medical and therapy data**
Intelligent production and services	Smart machines and clinical workflows	Individualized and adapted therapies
▪ Predictive maintenance ▪ Intelligent production capacity planning ▪ Automated testing environment	▪ Automated alarm management ▪ Intelligent Ultra Filtration	▪ Reduction of dropout rates in Home patients ▪ Individualized comorbidity management ▪ Transitional care by data and diagnostics

Convenience Efficiency **Outcome/Efficiency**

IN HEALTH CARE, DATA HAS ALSO GROWN EXPONENTIALLY

HOW DO WE MAKE SENSE OF IT ALL?

Electronic Medical Records

Patient Data

Machine Data

Genetics

Environment

Wearables

THE EVOLUTION OF DIGITAL DATA UTILITY



DIGITAL SKILLSETS AND CAPABILITIES NEEDED

Domain Experts

(e.g., physician)

define the goal, help other team members to grasp the relevance of real-life questions.

Data Scientists

use analytical and technical capabilities to extract meaningful insights from data.

Data Engineers

ensure uninterrupted flow of data between servers and applications. They are responsible for data architecture.

Statisticians

use theoretical expertise in statistics and apply them to real life problems.

Mathematicians

use mathematical modeling and computational methods to solve practical problems.

CARDIOVASCULAR PROTECTION FOR KIDNEY PATIENTS



BROADEST DATA SET IN THE WORLD ON ADVANCED KIDNEY DISEASE

GLOBAL NUMBERS

2,138,564
Patients

567,797,521
HD treatments

1,972,926,596
Labs

36,860,636
Comorbidities

1,548,575,115
In-center medications

2,972,171,527
Home medications

OUR CONNECTED HEALTH MACHINE

kinexus
Connecting You



Patient data
Fresenius Dialysis machine supported by peripherals and Home Patient App collects patient data

Kinexus Gateway
Data is securely transferred via Bluetooth, Wi-Fi or wired

Kinexus Cloud
In secured cloud data is stored and analyzed with medical algorithms

Clinical Care
Have access to analyzed patient data on their computer or mobile device

GENOMICS | OVERVIEW

Frenova® Renal Research

Vision

Catalyze increased innovation and investment in renal research

Goal

Build world largest renal registry; a curated database of clinical and genomic data



Strategy

Leverage existing FME's global footprint, vertical integration and diverse patient population

GENOMICS | VALUE CREATION

APPLICATION OF GENOMICS AND PRECISION MEDICINE ASSET AND CAPABILITY BY FMC PARTNERS AND PROVIDERS

Academic research

- Causes of kidney disease(s)
- Early diagnosis and monitoring biomarkers
- CKD and ESRD risk factors

Pharmaceutical R&D

- New therapeutic drug targets
- Translatable Kidney disease models
- Targeted clinical trials with reduced cost and time

Patient care

- Optimized therapies for targeted patient groups
- Improving transplant outcomes with more precise tissue typing/ post-transplant care
- Refined risk models and target interventions

MY Reason Transforming Kidney Research

CLINICAL TRIALS BY MEDICAL DISCIPLINE



KEY AREAS OF APPLIED ADVANCED ANALYTICS EFFORTS

Event prediction



Treatment Aid

Condition Diagnosis



Mathematical modeling and algorithms

Delivery of personalized care and optimization of multiple processes within the business

HOW DOES ARTIFICIAL INTELLIGENCE FIT INTO A DIGITALIZATION PLAN?

Artificial intelligence
A program that enables computers to mimic human behavior.



Machine learning
Subset of AI that uses statistical methods to build programs and whose performance improves when exposed to large amounts of data.

Deep learning
Subset of machine learning in which multilayered neural networks learn from vast amounts of data.

CAN WE CREATE A VIRTUAL CLINICAL TRIAL?

Can we use mathematical principles and create virtual "clinical" trials?
A Virtual Clinical Trial enables testing of multiple interventions in a random large sample of patients

Target population



Random sample

Virtual trials

Patients are represented as mathematical constructs ("Patient avatars")



SIMULATION OF ESA RESPONSE IN INDIVIDUAL PATIENTS

A standard of care anemia treatment protocol was tested in ~6,700 Avatars for one virtual year and compared to one year of data from ~6,700 anemia patients treated with the same protocol

Distribution of hemoglobin values



Frequency of ESA dose administration



Fuertinger et al., CPT Pharmacometr. Syst. Pharmacol. (2018) | Clinical data VIAT 3.0

MAKING THE DIGITAL DATA APPLY TO CLINICAL CARE



A MODEL FOR COVID PREDICTION RISK

INPUTS AND OUTPUT



Prediction	Reason 1	Reason 2	Reason 3
0.94	Monocytes: Change from previous month = **6.65**	IDWG: Change from previous month = **-1.82**	Albumin: 2-week average = **2.9**
0.92	County incidence: 3-day span = **0.001**	WBC count: Change from previous month = **-3.26**	IDWG: Change from previous month = **-2.054**
0.91	Monocytes: Change from previous month = **3.375**	County incidence: 3-day span = **0.001**	County incidence: 3-week span = **0.001**
0.91	County incidence: 3-day span = **0.002**	Monocytes: Change from previous month = **4.033**	County incidence: 3-week span = **0.001**
0.91	Albumin: 2-week average = **2.6**	IDWG: Change from previous month = **-4.377**	Post-HD Temperature: Change from previous month = **1.108**[1]

1 ~0.6 C

FRESENIUS MEDICAL CARE

Your Questions Are Welcome!



FINANCIAL CALENDAR 2021

REPORTING DATES & AGM

May 6	Q1 2021 Earnings Release and Conference Call
May 20	Annual General Meeting 2021 (Virtual)
July 30	Q2 2021 Earnings Release and Conference Call
November 2	Q3 2021 Earnings Release and Conference Call

CONFERENCES & MEET THE MANAGMENT

May 11-13	Bank of America Merrill Lynch Global Healthcare Conference
May 18	RBC Capital Markets Global Healthcare Conference
May 26-27	UBS Best of Europe One-on-One Virtual Conference

Please note that dates and/or participation might be subject to change

CONTACTS

FME INVESTOR RELATIONS

Else-Kröner-Str. 1

61352 Bad Homburg v.d.H.
Germany

TICKER:
FME or FMS (NYSE)

WKN:
578 580

ISIN:
DE00057858002

DR. DOMINIK HEGER

Head of Investor Relations,
Strategic Development &
Communications | EVP

+49(0) 6172-609-2601
dominik.heger@fmc-ag.com

ROBERT ADOLPH

Vice President
Investor Relations

+49(0) 6172-609-2477
robert.adolph@fmc-ag.com

PHILIPP GEBHARDT

Director
Investor Relations

+49(0) 6172-609-95011
philipp.gebhardt@fmc-ag.com

ALICIA CAHILL

Senior Manager
Investor Relations

+1 860-609-2394
alicia.cahill@fmc-ag.com